Dyskeratosis Congenita
Symptoms, Doctors, Treatments, Advances & More

Learn About Dyskeratosis Congenita

What is the definition of Dyskeratosis Congenita?

Dyskeratosis congenita is a disorder that can affect many parts of the body. There are three features that are characteristic of this disorder: fingernails and toenails that grow poorly or are abnormally shaped (nail dystrophy); changes in skin coloring (pigmentation), especially on the neck and chest, in a pattern often described as "lacy"; and white patches inside the mouth (oral leukoplakia).

What are the causes of Dyskeratosis Congenita?

In about half of people with dyskeratosis congenita, the disorder is caused by mutations in the TERT, TERC, DKC1, or TINF2 gene. These genes provide instructions for making proteins that help maintain structures known as telomeres, which are found at the ends of chromosomes. In a small number of individuals with dyskeratosis congenita, mutations in other genes involved with telomere maintenance have been identified. Other affected individuals have no mutations in any of the genes currently associated with dyskeratosis congenita. In these cases, the cause of the disorder is unknown, but other unidentified genes related to telomere maintenance are likely involved.

How prevalent is Dyskeratosis Congenita?

The exact prevalence of dyskeratosis congenita is unknown. It is estimated to occur in approximately 1 in 1 million people.

Is Dyskeratosis Congenita an inherited disorder?

Dyskeratosis congenita can have different inheritance patterns.

Who are the top Dyskeratosis Congenita Local Doctors?
Elite in Dyskeratosis Congenita
Elite in Dyskeratosis Congenita
Referral may be required
Aachen, NW, DE 

Fabian Beier practices practicing medicine in Aachen, Germany. Mr. Beier is rated as an Elite expert by MediFind in the treatment of Dyskeratosis Congenita. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Dyskeratosis Congenita, Aplastic Anemia, Anemia, Acquired Amegakaryocytic Thrombocytopenia, and Bone Marrow Transplant.

Elite in Dyskeratosis Congenita
Elite in Dyskeratosis Congenita
Referral may be required
Aachen, NW, DE 

Tim Brummendorf practices practicing medicine in Aachen, Germany. Mr. Brummendorf is rated as an Elite expert by MediFind in the treatment of Dyskeratosis Congenita. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Dyskeratosis Congenita, Leukemia, Myeloproliferative Neoplasms (MPN), and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Dyskeratosis Congenita
Elite in Dyskeratosis Congenita
Referral may be required
London, ENG, GB 

Inderjeet Dokal practices practicing medicine in London, United Kingdom. Dokal is rated as an Elite expert by MediFind in the treatment of Dyskeratosis Congenita. They are also highly rated in 4 other conditions, according to our data. Their clinical expertise encompasses Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Aplastic Anemia, and Anemia.

What are the latest Dyskeratosis Congenita Clinical Trials?
Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study

Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic cancers. Patients with IBMFS who develop cancer differ in their genetic and/or environmental features from patients with IBMFS who do not develop cancer. These cancer-...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Nucleoside Therapy in Patients With Telomere Biology Disorders

Summary: The goal of this clinical trial is to learn if a combination therapy of deoxycytidine (dC) plus deoxythymidine (dT) is safe in patients with telomere biology disorders. The main questions it aims to answer are: * Is the therapy safe with tolerable side effects in patients with telomere biology disorders? * Are problems with the bone marrow or blood or lungs changed after 6 months of dC+dT treatmen...

Who are the sources who wrote this article ?

Published Date: March 01, 2014
Published By: National Institutes of Health